Predicting primary treatment failure using interim FDG‐PET scanning in Diffuse large B‐cell lymphoma

Author(s):  
Joel Wight ◽  
Shin Hnin Wai ◽  
Edward Shen ◽  
Sze‐Ting Lee ◽  
Salvatore Berlangieri ◽  
...  
2021 ◽  
Vol 14 (10) ◽  
pp. 101188
Author(s):  
Raoul Santiago ◽  
Johanna Ortiz Jimenez ◽  
Reza Forghani ◽  
Nikesh Muthukrishnan ◽  
Olivier Del Corpo ◽  
...  

2018 ◽  
Vol 60 (4) ◽  
pp. 940-946
Author(s):  
Talha Badar ◽  
Mehdi Hamadani ◽  
Veronika Bachanova ◽  
Kami J. Maddocks ◽  
Elvira Umyarova ◽  
...  

2017 ◽  
Vol 92 (2) ◽  
pp. e24615 ◽  
Author(s):  
Luciano J. Costa ◽  
Kami Maddocks ◽  
Narendranath Epperla ◽  
Nishitha M. Reddy ◽  
Reem Karmali ◽  
...  

2021 ◽  
pp. 1-9
Author(s):  
François Allioux ◽  
Damaj Gandhi ◽  
Jean-Pierre Vilque ◽  
Cathy Nganoa ◽  
Anne-Claire Gac ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Pierre Decazes ◽  
Vincent Camus ◽  
Elodie Bohers ◽  
Pierre-Julien Viailly ◽  
Hervé Tilly ◽  
...  

Abstract Background 18F-FDG PET/CT is a standard for many B cell malignancies, while blood DNA measurements are emerging tools. Our objective was to evaluate the correlations between baseline PET parameters and circulating DNA in diffuse large B cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL). Methods Twenty-seven DLBCL and forty-eight cHL were prospectively included. Twelve PET parameters were analysed. Spearman’s correlations were used to compare PET parameters each other and to circulating cell-free DNA ([cfDNA]) and circulating tumour DNA ([ctDNA]). p values were controlled by Benjamini–Hochberg correction. Results Among the PET parameters, three different clusters for tumour burden, fragmentation/massiveness and dispersion parameters were observed. Some PET parameters were significantly correlated with blood DNA parameters, including the total metabolic tumour surface (TMTS) describing the tumour–host interface (e.g. ρ = 0.81 p < 0.001 for [ctDNA] of DLBLC), the tumour median distance between the periphery and the centroid (medPCD) describing the tumour’s massiveness (e.g. ρ = 0.81 p < 0.001 for [ctDNA] of DLBLC) and the volume of the bounding box including tumours (TumBB) describing the disease’s dispersion (e.g. ρ = 0.83 p < 0.001 for [ctDNA] of DLBLC). Conclusions Some PET parameters describing tumour burden, fragmentation/massiveness and dispersion are significantly correlated with circulating DNA parameters of DLBCL and cHL patients. These results could help to understand the pathophysiology of B cell malignancies.


2019 ◽  
Vol 61 (1) ◽  
pp. 40-45 ◽  
Author(s):  
Anne-Ségolène Cottereau ◽  
Christophe Nioche ◽  
Anne-Sophie Dirand ◽  
Jérôme Clerc ◽  
Franck Morschhauser ◽  
...  

2017 ◽  
Vol 114 (36) ◽  
pp. E7441-E7449 ◽  
Author(s):  
Jun Tang ◽  
Darin Salloum ◽  
Brandon Carney ◽  
Christian Brand ◽  
Susanne Kossatz ◽  
...  

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults. DLBCL exhibits highly aggressive and systemic progression into multiple tissues in patients, particularly in lymph nodes. Whole-body 18F-fluodeoxyglucose positron emission tomography ([18F]FDG-PET) imaging has an essential role in diagnosing DLBCL in the clinic; however, [18F]FDG-PET often faces difficulty in differentiating malignant tissues from certain nonmalignant tissues with high glucose uptake. We have developed a PET imaging strategy for DLBCL that targets poly[ADP ribose] polymerase 1 (PARP1), the expression of which has been found to be much higher in DLBCL than in healthy tissues. In a syngeneic DLBCL mouse model, this PARP1-targeted PET imaging approach allowed us to discriminate between malignant and inflamed lymph nodes, whereas [18F]FDG-PET failed to do so. Our PARP1-targeted PET imaging approach may be an attractive addition to the current PET imaging strategy to differentiate inflammation from malignancy in DLBCL.


Medicine ◽  
2015 ◽  
Vol 94 (29) ◽  
pp. e1210 ◽  
Author(s):  
Huiting Xu ◽  
Kai Xu ◽  
Ru Wang ◽  
Xiaohua Liu

Sign in / Sign up

Export Citation Format

Share Document